{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:37:55Z","timestamp":1715819875310},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,15]]},"DOI":"10.7759\/cureus.60356","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T16:00:29Z","timestamp":1715788829000},"source":"Crossref","is-referenced-by-count":0,"title":["Acute Noninfectious Anterior Ocular Inflammation Following Ranibizumab Biosimilar Intravitreal Injection in a Patient With Recent COVID-19 Vaccination"],"prefix":"10.7759","author":[{"given":"Ryo","family":"Tetsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Matsumiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Sotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sentaro","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1389450122999210128180725","article-title":"Anti-VEGF therapy in myopic CNV","volume":"22","author":"Toto L","year":"2021","unstructured":"Toto L, Di Antonio L, Costantino O, Mastropasqua R. Anti-VEGF therapy in myopic CNV. Curr Drug Targets. 2021, 22:1054-63. 10.2174\/1389450122999210128180725","journal-title":"Curr Drug Targets"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181a94f01","article-title":"Intravitreal injection of therapeutic agents","volume":"29","author":"Peyman GA","year":"2009","unstructured":"Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009, 29:875-912. 10.1097\/IAE.0b013e3181a94f01","journal-title":"Retina"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/943409","article-title":"Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy","volume":"2013","author":"Agrawal S","year":"2013","unstructured":"Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm. 2013, 2013:943409. 10.1155\/2013\/943409","journal-title":"Mediators Inflamm"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn1755","article-title":"COVID-19 vaccination: the road ahead","volume":"375","author":"Altmann DM","year":"2022","unstructured":"Altmann DM, Boyton RJ. COVID-19 vaccination: the road ahead. Science. 2022, 375:1127-32. 10.1126\/science.abn1755","journal-title":"Science"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.05.015","article-title":"Association between vaccination with the BNT162b2 mRNA coronavirus disease 2019 vaccine and noninfectious uveitis: a population-based study","volume":"129","author":"Tomkins-Netzer O","year":"2022","unstructured":"Tomkins-Netzer O, Sar S, Barnett-Griness O, Friedman B, Shyriaieva H, Saliba W. Association between vaccination with the BNT162b2 mRNA coronavirus disease 2019 vaccine and noninfectious uveitis: a population-based study. Ophthalmology. 2022, 129:1087-95. 10.1016\/j.ophtha.2022.05.015","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/2474126418806832","article-title":"Distinguishing between infectious endophthalmitis and noninfectious inflammation following intravitreal anti-VEGF injection","volume":"3","author":"Schwartz SG","year":"2018","unstructured":"Schwartz SG, Emerson GG, Choudhry N, Ferrone PJ, Goldberg RA, Lim JI, Witkin AJ. Distinguishing between infectious endophthalmitis and noninfectious inflammation following intravitreal anti-VEGF injection. J Vitreoretin Dis. 2018, 3:42-4. 10.1177\/2474126418806832","journal-title":"J Vitreoretin Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02246-5","article-title":"Approved biosimilar ranibizumab-a global update","volume":"37","author":"Sharma A","year":"2023","unstructured":"Sharma A, Kondo M, Iwahashi C, et al.. Approved biosimilar ranibizumab-a global update. Eye (Lond). 2023, 37:200-2. 10.1038\/s41433-022-02246-5","journal-title":"Eye (Lond)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2015.1090004","article-title":"Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: a retrospective claims database analysis","volume":"23","author":"Souied EH","year":"2016","unstructured":"Souied EH, Dugel PU, Ferreira A, Hashmonay R, Lu J, Kelly SP. Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: a retrospective claims database analysis. Ophthalmic Epidemiol. 2016, 23:71-9. 10.3109\/09286586.2015.1090004","journal-title":"Ophthalmic Epidemiol"},{"key":"ref9","article-title":"Phase \u2162 clinical trial to verify the equivalence between ranibizumab (genetic recombination) biosimilar (SJP-0133) and a ranibizumab reference product in patients with wet age-related macular degeneration and evaluate the long-term safety and efficacy of SJP-0133","volume":"39","author":"Kondo M","year":"2022","unstructured":"Kondo M, Ogura Y, Takahashi K, et al.. Phase \u2162 clinical trial to verify the equivalence between ranibizumab (genetic recombination) biosimilar (SJP-0133) and a ranibizumab reference product in patients with wet age-related macular degeneration and evaluate the long-term safety and efficacy of SJP-0133. J Eye. 2022, 39:1421-34.","journal-title":"J Eye"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson WJ","year":"2021","unstructured":"Anderson WJ, da Cruz NF, Lima LH, Emerson GG, Rodrigues EB, Melo GB. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retina Vitreous. 2021, 7:37. 10.1186\/s40942-021-00307-7","journal-title":"Int J Retina Vitreous"},{"key":"ref11","article-title":"Guidelines for intravitreal injection for macular diseases [Article in Japanese]","volume":"120","author":"Ogura Y","year":"2016","unstructured":"Ogura Y, Takahashi K, Iida T. Guidelines for intravitreal injection for macular diseases [Article in Japanese]. Nippon Ganka Gakkai Zasshi. 2016, 120:87-90.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"ref12","article-title":"Vaccine-associated uveitis","volume":"113","author":"Benage M","year":"2016","unstructured":"Benage M, Fraunfelder FW. Vaccine-associated uveitis. Mo Med. 2016, 113:48-52.","journal-title":"Mo Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2023-324503","article-title":"Ocular inflammatory events following COVID-19 vaccination: reporting of suspected adverse drug reactions to regulatory authorities in the UK","author":"Testi I","year":"2024","unstructured":"Testi I, Soomro T, Pavesio C, Solebo AL. Ocular inflammatory events following COVID-19 vaccination: reporting of suspected adverse drug reactions to regulatory authorities in the UK. Br J Ophthalmol. 2024, 10.1136\/bjo-2023-324503","journal-title":"Br J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.08.027","article-title":"Vaccine-associated uveitis after COVID-19 vaccination: vaccine adverse event reporting system database analysis","volume":"130","author":"Singh RB","year":"2023","unstructured":"Singh RB, Parmar UP, Kahale F, Agarwal A, Tsui E. Vaccine-associated uveitis after COVID-19 vaccination: vaccine adverse event reporting system database analysis. Ophthalmology. 2023, 130:179-86. 10.1016\/j.ophtha.2022.08.027","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11010069","article-title":"The characteristics of COVID-19 vaccine-associated uveitis: a summative systematic review","volume":"11","author":"Cherif YY","year":"2022","unstructured":"Cherif YY, Djeffal C, Abu Serhan H, et al.. The characteristics of COVID-19 vaccine-associated uveitis: a summative systematic review. Vaccines (Basel). 2022, 11:69. 10.3390\/vaccines11010069","journal-title":"Vaccines (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18088","article-title":"Transient inflammation in surgical scars following Covid-19 mRNA vaccination","volume":"36","author":"Ferreli C","year":"2022","unstructured":"Ferreli C, Anedda J, Atzori L. Transient inflammation in surgical scars following Covid-19 mRNA vaccination. J Eur Acad Dermatol Venereol. 2022, 36:e530-1. 10.1111\/jdv.18088","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_414_23","article-title":"Wolf's isotopic response following COVID-19 vaccination","volume":"68","author":"Hsu HT","year":"2023","unstructured":"Hsu HT, Su HA, Chen YC. Wolf's isotopic response following COVID-19 vaccination. Indian J Dermatol. 2023, 68:589. 10.4103\/ijd.ijd_414_23","journal-title":"Indian J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101532","article-title":"Multiple evanescent white dot syndrome following BNT162b2 mRNA COVID-19 vaccination","volume":"26","author":"Yasuda E","year":"2022","unstructured":"Yasuda E, Matsumiya W, Maeda Y, Kusuhara S, Nguyen QD, Nakamura M, Hara R. Multiple evanescent white dot syndrome following BNT162b2 mRNA COVID-19 vaccination. Am J Ophthalmol Case Rep. 2022, 26:101532. 10.1016\/j.ajoc.2022.101532","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15241","article-title":"New-onset bullous pemphigoid after inactivated Covid-19 vaccine: synergistic effect of the Covid-19 vaccine and vildagliptin","volume":"35","author":"Bostan E","year":"2022","unstructured":"Bostan E, Yel B, Akdogan N, Gokoz O. New-onset bullous pemphigoid after inactivated Covid-19 vaccine: synergistic effect of the Covid-19 vaccine and vildagliptin. Dermatol Ther. 2022, 35:e15241. 10.1111\/dth.15241","journal-title":"Dermatol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/ans.16196","article-title":"Surgery triage during the COVID-19 pandemic","volume":"90","author":"Babidge WJ","year":"2020","unstructured":"Babidge WJ, Tivey DR, Kovoor JG, et al.. Surgery triage during the COVID-19 pandemic. ANZ J Surg. 2020, 90:1558-65. 10.1111\/ans.16196","journal-title":"ANZ J Surg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/255543-acute-noninfectious-anterior-ocular-inflammation-following-ranibizumab-biosimilar-intravitreal-injection-in-a-patient-with-recent-covid-19-vaccination","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T16:00:34Z","timestamp":1715788834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/255543-acute-noninfectious-anterior-ocular-inflammation-following-ranibizumab-biosimilar-intravitreal-injection-in-a-patient-with-recent-covid-19-vaccination"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.60356","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,15]]}}}